Suven Life Sciences Begins Phase-2B Trial for Ropanicant in MDD, Marks Key Milestone in CNS Drug Development

Unknown Apr 02, 2026 1,200 Views

Suven Life Sciences Ltd has announced the randomization of the first patient in its Phase-2B clinical trial for Ropanicant (SUVN-911), a novel α4β2 nAChR antagonist being developed for moderate to severe Major Depressive Disorder (MDD). The trial represents a critical step in validatin...